AU2014217564B2 - Highly galactosylated anti-HER2 antibodies and uses thereof - Google Patents

Highly galactosylated anti-HER2 antibodies and uses thereof Download PDF

Info

Publication number
AU2014217564B2
AU2014217564B2 AU2014217564A AU2014217564A AU2014217564B2 AU 2014217564 B2 AU2014217564 B2 AU 2014217564B2 AU 2014217564 A AU2014217564 A AU 2014217564A AU 2014217564 A AU2014217564 A AU 2014217564A AU 2014217564 B2 AU2014217564 B2 AU 2014217564B2
Authority
AU
Australia
Prior art keywords
antibodies
ser
val
population
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014217564A
Other languages
English (en)
Other versions
AU2014217564A1 (en
Inventor
Li-How Chen
Harry M. Meade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of AU2014217564A1 publication Critical patent/AU2014217564A1/en
Application granted granted Critical
Publication of AU2014217564B2 publication Critical patent/AU2014217564B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
AU2014217564A 2013-02-13 2014-02-13 Highly galactosylated anti-HER2 antibodies and uses thereof Ceased AU2014217564B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764488P 2013-02-13 2013-02-13
US61/764,488 2013-02-13
PCT/IB2014/000711 WO2014125377A2 (en) 2013-02-13 2014-02-13 Highly galactosylated anti-her2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2014217564A1 AU2014217564A1 (en) 2015-08-27
AU2014217564B2 true AU2014217564B2 (en) 2018-11-08

Family

ID=50980322

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014217564A Ceased AU2014217564B2 (en) 2013-02-13 2014-02-13 Highly galactosylated anti-HER2 antibodies and uses thereof

Country Status (13)

Country Link
US (1) US20150368357A1 (enExample)
EP (1) EP2956485A2 (enExample)
JP (2) JP2016509019A (enExample)
KR (1) KR20160003634A (enExample)
CN (1) CN105308071A (enExample)
AR (1) AR094781A1 (enExample)
AU (1) AU2014217564B2 (enExample)
BR (1) BR112015019343A2 (enExample)
CA (1) CA2900912A1 (enExample)
IL (1) IL240440A0 (enExample)
MX (1) MX2015010428A (enExample)
TW (1) TW201444870A (enExample)
WO (1) WO2014125377A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501365A1 (en) 2010-12-30 2013-09-16 Laboratoire Francais Du Fractionnment Et Des Biotechnologies Glycols as pathogen inactivating agents
BR112015019341A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
JP2016532100A (ja) 2013-07-05 2016-10-13 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ アフィニティークロマトグラフィーマトリックス
CN114181312A (zh) * 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
FR3060395B1 (fr) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-her2
MX2020013036A (es) * 2018-06-05 2021-02-26 Amgen Inc Modulacion de la fagocitosis celular dependiente de anticuerpos.
EP3806905B1 (en) * 2018-06-15 2024-08-07 Shanghai Miracogen Inc. Methods and materials for treating cancer
CN113999313A (zh) * 2020-07-28 2022-02-01 百奥泰生物制药股份有限公司 抗her2抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292273A2 (en) * 2001-10-10 2011-03-09 BioGeneriX AG Remodeling and glycoconjugation of peptides

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
JP4334141B2 (ja) * 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20040101939A1 (en) * 2002-11-22 2004-05-27 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
NZ568433A (en) * 2005-10-21 2012-07-27 Gtc Biotherapeutics Inc Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20100173323A1 (en) * 2006-06-09 2010-07-08 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
ES2661952T3 (es) * 2006-08-04 2018-04-04 Medimmune Limited Anticuerpos humanos contra ERBB2
HRP20150307T1 (hr) * 2006-09-10 2015-04-24 Glycotope Gmbh Upotreba ljudskih stanica podrijetlom iz ljudske leukemije za eksprimiranje protutijela
CN101588817B (zh) * 2006-09-10 2013-06-12 葛莱高托普有限公司 骨髓白血病来源的细胞在抗体表达中的用途
EP2725035A1 (en) * 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US8080415B2 (en) * 2008-09-26 2011-12-20 Eureka Therapeutics, Inc. Modified host cells and uses thereof
JPWO2012105699A1 (ja) * 2011-02-03 2014-07-03 株式会社イーベック 補体依存性生物活性の高い抗体の産生法
AU2012203048A1 (en) * 2011-05-24 2012-12-13 Agency For Science, Technology And Research IRES mediated multicistronic vectors
BR112015019341A2 (pt) * 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292273A2 (en) * 2001-10-10 2011-03-09 BioGeneriX AG Remodeling and glycoconjugation of peptides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ATSUHIKO TOYAMA ET AL, "Quantitative Structural Characterization of Local N-Glycan Microheterogeneity in Therapeutic Antibodies by Energy-Resolved Oxonium Ion Monitoring", ANALYTICAL CHEMISTRY, vol. 84, no. 22, pages 9655 - 9662 *
HODONICZKY J ET AL, "Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro", BIOTECHNOLOGY PROGRESS, AMERICAN INSTITUTE OF CHEMICAL ENGINEERS, US, (2005-10-07), vol. 21, no. 6, pages 1644 - 1652 *
POLLOCK D P ET AL, "Transgenic milk as a method for the production of recombinant antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, (1999-12-10), vol. 231, no. 1-2, pages 147 - 157 *
RAJU T S ET AL, GLYCOBIOLOGY, vol. 10, no. 5, pages 477 - 486 *
YUSKEVICH, V. et al "Expression of humanised anti-Her2/neu single-chain IgG1-like antibody in mammary glands of transgenic mice." Biochimie, Vol. 93, p. 628-630. 2011 *

Also Published As

Publication number Publication date
EP2956485A2 (en) 2015-12-23
AR094781A1 (es) 2015-08-26
TW201444870A (zh) 2014-12-01
MX2015010428A (es) 2016-04-13
CA2900912A1 (en) 2014-08-21
KR20160003634A (ko) 2016-01-11
AU2014217564A1 (en) 2015-08-27
US20150368357A1 (en) 2015-12-24
JP2020125286A (ja) 2020-08-20
WO2014125377A3 (en) 2014-12-04
IL240440A0 (en) 2015-09-24
JP2016509019A (ja) 2016-03-24
CN105308071A (zh) 2016-02-03
BR112015019343A2 (pt) 2017-08-22
WO2014125377A2 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
AU2014217564B2 (en) Highly galactosylated anti-HER2 antibodies and uses thereof
EP2741769B1 (en) Highly galactosylated antibodies
US10174110B2 (en) Highly galactosylated anti-TNF-α antibodies and uses thereof
AU2006304886B2 (en) Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
AU2012293420B2 (en) Highly galactosylated antibodies
AU2012201010B2 (en) Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
AU2015201981A1 (en) Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired